Draflazine is primarily used in medical research due to its properties as a potent and selective adenosine uptake inhibitor. It is often employed in studies to understand the role of adenosine in various physiological processes, particularly in the cardiovascular and nervous systems. By blocking adenosine reuptake, it increases extracellular adenosine levels, which helps in examining its effects on vasodilation, neurotransmission, and anti-inflammatory responses. This makes it a valuable tool in exploring potential therapeutic applications for conditions like ischemia, arrhythmias, and neurodegenerative diseases. Additionally, it is used in pharmacological experiments to investigate adenosine receptor signaling pathways and their implications in disease mechanisms.